FDA Lifts Partial Clinical Hold on Tellomak Trial with Lacutamab in Advanced T-Cell Lymphomas

The U.S. FDA has lifted a partial clinical hold that had been placed on the phase 2 TELLOMAK trial which is examining the safety and efficacy of lacutamab in patients with advanced T-cell lymphoma, according to an announcement from the drug’s developer, Innate Pharma SA. The decision is based on a quality assessment of a new Good Manufacturing Practice (GMP)-certified batch that has been successfully manufactured for the clinical development program for the agent, which includes TELLOMAK. In light of this feedback, the commercial stage oncology-focused biotech company can now recommence moving forward. Learn More